Is ABVC Biopharma Stock a Good Investment?
ABVC Biopharma Investment Advice | ABVC |
- Examine ABVC Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ABVC Biopharma's leadership team and their track record. Good management can help ABVC Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ABVC Biopharma's business and its evolving consumer preferences.
- Compare ABVC Biopharma's performance and market position to its competitors. Analyze how ABVC Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if ABVC Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ABVC Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ABVC Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ABVC Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ABVC Biopharma Stock
Researching ABVC Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. ABVC Biopharma recorded a loss per share of 0.81. The entity last dividend was issued on the 8th of May 2019. The firm had 1:10 split on the 25th of July 2023.
To determine if ABVC Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ABVC Biopharma's research are outlined below:
| ABVC Biopharma is way too risky over 90 days horizon | |
| ABVC Biopharma has some characteristics of a very speculative penny stock | |
| ABVC Biopharma appears to be risky and price may revert if volatility continues | |
| ABVC Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 152.43 K. Net Loss for the year was (10.52 M) with profit before overhead, payroll, taxes, and interest of 369.82 K. | |
| ABVC Biopharma currently holds about 2.99 M in cash with (4.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| ABVC Biopharma has a very weak financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential |
ABVC Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ABVC Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ABVC Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact ABVC Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ABVC Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2021-11-15 | 2021-09-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2021-08-12 | 2021-06-30 | -0.04 | -0.08 | -0.04 | 100 | ||
2022-08-15 | 2022-06-30 | -0.12 | -0.06 | 0.06 | 50 | ||
2021-03-16 | 2020-12-31 | -0.1 | -0.24 | -0.14 | 140 | ||
2022-03-31 | 2021-12-31 | -0.04 | -0.31 | -0.27 | 675 | ||
2023-08-14 | 2023-06-30 | -0.06 | -0.6841 | -0.6241 | 1040 | ||
2023-11-15 | 2023-09-30 | -0.04 | -0.8181 | -0.7781 | 1945 |
Know ABVC Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ABVC Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ABVC Biopharma backward and forwards among themselves. ABVC Biopharma's institutional investor refers to the entity that pools money to purchase ABVC Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 81.0 | Ubs Group Ag | 2024-12-31 | 10.0 | Honkamp Krueger Financial Services Inc | 2024-12-31 | 144 K | Geode Capital Management, Llc | 2024-12-31 | 79.3 K | Vanguard Group Inc | 2024-12-31 | 46.9 K | Citadel Advisors Llc | 2024-12-31 | 40.7 K | Xtx Topco Ltd | 2024-12-31 | 34.4 K | Northern Trust Corp | 2024-12-31 | 19.1 K | Virtu Financial Llc | 2024-12-31 | 15.9 K | State Street Corp | 2024-12-31 | 12.9 K | Two Sigma Securities, Llc | 2024-12-31 | 12.6 K |
ABVC Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.76 M.Market Cap |
|
ABVC Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.83) | (0.88) | |
| Return On Capital Employed | (1.10) | (1.16) | |
| Return On Assets | (0.83) | (0.88) | |
| Return On Equity | (1.13) | (1.18) |
Determining ABVC Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if ABVC Biopharma is a good buy. For example, gross profit margin measures ABVC Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ABVC Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of ABVC Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ABVC Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ABVC Biopharma's management manipulating its earnings.
Evaluate ABVC Biopharma's management efficiency
ABVC Biopharma has return on total asset (ROA) of (0.253) % which means that it has lost $0.253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0232) %, meaning that it created substantial loss on money invested by shareholders. ABVC Biopharma's management efficiency ratios could be used to measure how well ABVC Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.88. In addition to that, Return On Capital Employed is expected to decline to -1.16. At present, ABVC Biopharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 15.5 M, whereas Total Current Assets are forecasted to decline to about 1.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.69 | 1.77 | |
| Tangible Book Value Per Share | 1.69 | 1.77 | |
| Enterprise Value Over EBITDA | (0.80) | (0.84) | |
| Price Book Value Ratio | 0.69 | 0.66 | |
| Enterprise Value Multiple | (0.80) | (0.84) | |
| Price Fair Value | 0.69 | 0.66 | |
| Enterprise Value | 94.5 M | 89.8 M |
The leadership approach at ABVC Biopharma's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 0.67 |
Basic technical analysis of ABVC Stock
As of the 22nd of March, ABVC Biopharma shows the Mean Deviation of 3.97, market risk adjusted performance of (1.32), and Coefficient Of Variation of 1102.65. ABVC Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.ABVC Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ABVC Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on ABVC Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ABVC Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ABVC Biopharma's Outstanding Corporate Bonds
ABVC Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ABVC Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ABVC bonds can be classified according to their maturity, which is the date when ABVC Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand ABVC Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ABVC Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0889 | |||
| Market Risk Adjusted Performance | (1.32) | |||
| Mean Deviation | 3.97 | |||
| Semi Deviation | 4.38 | |||
| Downside Deviation | 6.07 | |||
| Coefficient Of Variation | 1102.65 | |||
| Standard Deviation | 5.77 | |||
| Variance | 33.28 | |||
| Information Ratio | 0.1015 | |||
| Jensen Alpha | 0.4854 | |||
| Total Risk Alpha | 0.9837 | |||
| Sortino Ratio | 0.0965 | |||
| Treynor Ratio | (1.33) | |||
| Maximum Drawdown | 32.39 | |||
| Value At Risk | (8.62) | |||
| Potential Upside | 9.8 | |||
| Downside Variance | 36.83 | |||
| Semi Variance | 19.22 | |||
| Expected Short fall | (5.98) | |||
| Skewness | 0.4628 | |||
| Kurtosis | 1.96 |
| Risk Adjusted Performance | 0.0889 | |||
| Market Risk Adjusted Performance | (1.32) | |||
| Mean Deviation | 3.97 | |||
| Semi Deviation | 4.38 | |||
| Downside Deviation | 6.07 | |||
| Coefficient Of Variation | 1102.65 | |||
| Standard Deviation | 5.77 | |||
| Variance | 33.28 | |||
| Information Ratio | 0.1015 | |||
| Jensen Alpha | 0.4854 | |||
| Total Risk Alpha | 0.9837 | |||
| Sortino Ratio | 0.0965 | |||
| Treynor Ratio | (1.33) | |||
| Maximum Drawdown | 32.39 | |||
| Value At Risk | (8.62) | |||
| Potential Upside | 9.8 | |||
| Downside Variance | 36.83 | |||
| Semi Variance | 19.22 | |||
| Expected Short fall | (5.98) | |||
| Skewness | 0.4628 | |||
| Kurtosis | 1.96 |
Consider ABVC Biopharma's intraday indicators
ABVC Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ABVC Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ABVC Biopharma time-series forecasting models is one of many ABVC Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ABVC Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ABVC Stock media impact
Far too much social signal, news, headlines, and media speculation about ABVC Biopharma that are available to investors today. That information is available publicly through ABVC media outlets and privately through word of mouth or via ABVC internal channels. However, regardless of the origin, that massive amount of ABVC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ABVC Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ABVC Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ABVC Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ABVC Biopharma alpha.
ABVC Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ABVC Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ABVC Biopharma Corporate Management
| TsungShann Jiang | Member Officer | Profile | |
| Leeds Chow | Chief Officer | Profile | |
| Howard MD | Pres CEO | Profile | |
| ChiHsin King | Chief Officer | Profile | |
| Uttam Patil | Chief Officer | Profile | |
| Eugene Jiang | Chairman Officer | Profile |
Already Invested in ABVC Biopharma?
The danger of trading ABVC Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ABVC Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ABVC Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ABVC Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 23.507 | Return On Assets | Return On Equity |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between ABVC Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.